Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESIST: Tirzepatide and Resistance Exercise in ALL Survivors with Obesity
NCT07228741Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirzepatide in obesity, sponsored by St. Jude Children's Research Hospital. Primary endpoint: Proportion of participants achieving >=5% weight loss at 28 weeks. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07228741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228741.